Severity of hypoglycaemia and health‐related quality of life, work productivity and healthcare costs in patients with type 2 diabetes in Europe

Pawaskar, Manjiri; Witt, Edward A.; Engel, Samuel S.; Rajpathak, Swapnil; Iglay, Kristy

doi:10.1002/edm2.11

Cited by 15 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comparison of patients with NASH to patients with T2DM was of particular interest, as T2DM is a condition with a substantial, well-characterized, and well-known burden. [20][21][22][23] Our results extend our knowledge of the burden of NASH in multiple important ways.…”

Section: Discussionsupporting

confidence: 59%

The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study

et al. 2019

View full text Add to dashboard Cite

Highlights • Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease. • NASH imposes a significant humanistic and economic burden on individuals and society. • NASH impairs health-related quality of life, work productivity and activity, while increasing healthcare resource use. • This study highlights the unmet need of patients with NASH in the absence of any approved treatment.

show abstract

Section: Discussionsupporting

confidence: 59%

The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Competitive/partial mitochondrial Complex I inhibition; no decrease in mitochondrial respiration; decreased ROS b formation 44,51,55 Uncompetitive mitochondrial Complex I inhibition; decreased respiration 55,71 ; decreased ROS formation 76,77 No islets. 45 In this context there was no change in cellular NADH content but the NAD/NADH ratio was significantly increased by 30%-31%.…”

Section: Intracellularmentioning

confidence: 99%

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

Hallakou‐Bozec

Vial

Kergoat

et al. 2020

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Imeglimin is an investigational first‐in‐class novel oral agent for the treatment of type 2 diabetes (T2D). Several pivotal phase III trials have been completed with evidence of statistically significant glucose lowering and a generally favourable safety and tolerability profile, including the lack of severe hypoglycaemia. Imeglimin's mechanism of action involves dual effects: (a) amplification of glucose‐stimulated insulin secretion (GSIS) and preservation of β‐cell mass; and (b) enhanced insulin action, including the potential for inhibition of hepatic glucose output and improvement in insulin signalling in both liver and skeletal muscle. At a cellular and molecular level, Imeglimin's underlying mechanism may involve correction of mitochondrial dysfunction, a common underlying element of T2D pathogenesis. It has been observed to rebalance respiratory chain activity (partial inhibition of Complex I and correction of deficient Complex III activity), resulting in reduced reactive oxygen species formation (decreasing oxidative stress) and prevention of mitochondrial permeability transition pore opening (implicated in preventing cell death). In islets derived from diseased rodents with T2D, Imeglimin also enhances glucose‐stimulated ATP generation and induces the synthesis of nicotinamide adenine dinucleotide (NAD+) via the ‘salvage pathway’. In addition to playing a key role as a mitochondrial co‐factor, NAD+ metabolites may contribute to the increase in GSIS (via enhanced Ca++ mobilization). Imeglimin has also been shown to preserve β‐cell mass in rodents with T2D. Overall, Imeglimin appears to target a key root cause of T2D: defective cellular energy metabolism. This potential mode of action is unique and has been shown to differ from that of other major therapeutic classes, including biguanides, sulphonylureas and glucagon‐like peptide‐1 receptor agonists.

show abstract

“…HRQoL was assessed using the 36-Item short-form (SF-36v2) and the EuroQol 5 Dimension (EQ-5D) survey instruments. The SF-36v2 is a multipurpose, generic HRQoL instrument comprising 36 questions that map onto 8 health domains, and these relevant scores are summarized into the physical component summary (PCS) and the mental component summary (MCS) [15][16][17]. Higher scores indicate a better QoL.…”

Section: Definition Of Qolmentioning

confidence: 99%

Association between sleep disorder and quality of life in patients with type 2 diabetes: a cross-sectional study

et al. 2020

View full text Add to dashboard Cite

Background: We investigated the association between sleep symptoms, which cause sleep disorder, and quality of life (QoL) among people with type 2 diabetes (T2D). Methods: In this cross-sectional study of 342 people with T2D, the Japan National Health and Wellness Survey (NHWS) database 2016 were used. We treated the respondents who reported experiencing any of the sleep symptoms as having sleep disorders. To examine health-related QoL (HRQoL), we used the physical component summary (PCS) and the mental component summary (MCS) from the 36-Item short-form and the EuroQol 5 Dimension (EQ-5D) survey instruments. Overall activity impairment was used for assessment of the effect on the individual's ability to perform regular daily activities. We used t-test and one-way ANOVA test for comparison QoL scores between the participants with and without sleep disorders. Results: 66.4% of the participants with T2D reported having a sleep disorder. The PCS, MCS, EQ-5D, and overall activity impairment of people with sleep disorder was significantly poorer than those of the people without. Specific sleep symptoms, such as waking up to go to the bathroom, daytime sleepiness, and waking up too early (before the alarm clock), had high prevalence (35.4, 27.8 and 20.2%). The participants who experienced waking up to go to the bathroom or daytime sleepiness demonstrated significantly poorer QoL on all scores related to QoL, but those who experienced waking up too early only demonstrated significantly poorer QoL on the EQ-5D. Conclusions: Two-thirds of people with T2D in this study suffer from sleep disorders. The people who experience waking up to go to the bathroom or daytime sleepiness had significantly poorer QoL than those without these symptoms. Thus, sleep disorders, especially the symptoms of waking up to go to the bathroom or daytime sleepiness, might be the treatment targets for QOL of people with T2DM.

show abstract

Severity of hypoglycaemia and health‐related quality of life, work productivity and healthcare costs in patients with type 2 diabetes in Europe

Cited by 15 publications

References 38 publications

The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study

The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

Association between sleep disorder and quality of life in patients with type 2 diabetes: a cross-sectional study

Contact Info

Product

Resources

About